Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

ClinicalTrials.gov ID: NCT00312221

Public ClinicalTrials.gov record NCT00312221. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal system (5 mg) and oxycodone immediate release in subjects with moderate to severe osteoarthritis pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen, immediate release oxycodone) will be provided to all subjects in addition to study drug.

Study identification

NCT ID
NCT00312221
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Purdue Pharma LP
Industry
Enrollment
418 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2004
Primary completion
Jun 30, 2005
Completion
Jul 31, 2005
Last update posted
Sep 9, 2012

2004 – 2005

United States locations

U.S. sites
23
U.S. states
12
U.S. cities
21
Facility City State ZIP Site status
Parkway Medical Center Birmingham Alabama 35215
International Clinical Research Network Chula Vista California 91910
Clinical Trials Research Roseville California 95661
Accelovance San Diego California 92108
Torrance Clinical Research Torrance California 90505
Southern Colorado Clinic Pueblo Colorado 81008
Drug Study Institute Jupiter Florida 33458
Innovative Research of West Florida, Inc. Largo Florida 33770
International Medical Research Ormond Beach Florida 32174
Peninsula Research, Inc. Ormond Beach Florida 32174
Palm Beach Research Center West Palm Beach Florida 33409
Georgia Medical Research Institute Marietta Georgia 30060
Non- Surgical Orthopedic & Spine Center, P.C. Marietta Georgia 30060
The Arthritis Center Springfield Illinois 62704
Commonwealth Biomedical Research, LLC Madisonville Kentucky 42431
Miray Medical Center Brockton Massachusetts 23010
Professional Clinical Research Crystal Lake Health Center Benzonia Michigan 49616
Rheumatology PC Kalamazoo Michigan 49009
Pharm Quest Greensboro North Carolina 27401
The Clinical Trial Center, LLC Jenkintown Pennsylvania 19046
Amarillo Center for Clinical Research Amarillo Texas 79124
Med Search Professional Group/Pharmaceutical C-Trials Inc. Hurst Texas 76054
Texas Medical Research Associates San Antonio Texas 78238

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00312221, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2012 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00312221 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →